Skip to content
OpenCapital
Get started

Twist Bioscience Corporation TWST Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
Danaher logo
DanaherDHR
$5.7B+186%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Illumina logo
IlluminaILMN
$1.09B-2.2%
TEC
Bio-TechneTECH
$209.82M+49.2%
Revvity logo
RevvityRVTY
$861.47M-24.3%

Other financials

Income statement

See full
Revenue$110.7M+19.3%
Gross profit$57.1M+24.1%
Operating income-$45.9M-10.4%
Net income-$44.0M-11.9%
EPS (diluted)-$0.71-7.6%

Balance sheet

See full
Total debt$110.8M+16.3%
Total equity$455.1M+3.4%
Total assets$676.2M+13.5%

Cash flow

See full
Operating cash flow-$17.6M-35.2%
CapEx$7.9M+90.3%
Free cash flow-$25.4M-48.5%

Valuation

See full
Market cap$5.45B+24.4%

Profitability

See full
Gross margin52.1%+5.4pp
Operating margin-33.9%-9.9pp
Net margin-19.8%-7.7pp
FCF margin-23.2%+7.0pp

Returns & leverage

See full
Return on equity-18.2%-6.3pp
Debt / equity0.2×0.0×
Current ratio2.7×-1.8×

Where this comes from

Reported directly by Twist Bioscience Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Twist Bioscience Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Twist Bioscience Corporation's cash & equivalents?
Twist Bioscience Corporation (TWST) reported cash & equivalents of $124.85M in Q1 2026.
How has Twist Bioscience Corporation's cash & equivalents changed year-over-year?
Twist Bioscience Corporation's cash & equivalents decreased by 41.4% year-over-year, from $212.95M to $124.85M.
What is the long-term trend for Twist Bioscience Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Twist Bioscience Corporation's cash & equivalents has grown at a 14.5% compound annual growth rate (CAGR), from $94.25M to $185.43M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.